6.30
-0.19 (-2.93%)
| Previous Close | 6.49 |
| Open | 6.25 |
| Volume | 230,273 |
| Avg. Volume (3M) | 251,511 |
| Market Cap | 337,937,696 |
| Price / Sales | 37.47 |
| Price / Book | 0.740 |
| 52 Weeks Range | |
| Earnings Date | 12 Mar 2025 |
| Operating Margin (TTM) | -4,293.31% |
| Diluted EPS (TTM) | -5.58 |
| Quarterly Revenue Growth (YOY) | 36.20% |
| Total Debt/Equity (MRQ) | 0.39% |
| Current Ratio (MRQ) | 44.63 |
| Operating Cash Flow (TTM) | -59.17 M |
| Levered Free Cash Flow (TTM) | -40.98 M |
| Return on Assets (TTM) | -16.23% |
| Return on Equity (TTM) | -21.75% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Upstream Bio, Inc. | Mixed | - |
AIStockmoo Score
| Analyst Consensus | NA |
| Insider Activity | NA |
| Price Volatility | 0.5 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | -0.5 |
| Average | 0.83 |
|
Upstream Bio Inc is a clinical-stage biotechnology company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders. It is developing verekitug, the known antagonist currently in clinical development that targets the receptor for Thymic Stromal Lymphopoietin (TSLP), a cytokine which is a clinically validated driver of inflammatory response positioned upstream of multiple signaling cascades that affect a variety of immune mediated diseases. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| % Held by Insiders | 19.80% |
| % Held by Institutions | 87.82% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Decheng Capital Llc | 31 Dec 2024 | 3,285,293 |
| Tcg Crossover Management, Llc | 31 Dec 2024 | 2,801,763 |
| Enavate Sciences Gp, Llc | 31 Dec 2024 | 2,459,703 |
| Vr Adviser, Llc | 31 Dec 2024 | 2,295,319 |
| Samsara Biocapital, Llc | 31 Dec 2024 | 2,217,146 |
| Deep Track Capital, Lp | 31 Dec 2024 | 1,000,000 |
No data within this time range.
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 12 Mar 2025 | Announcement | Upstream Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights |
| 25 Feb 2025 | Announcement | Upstream Bio to Present at Upcoming March Investor Conferences |
| 11 Feb 2025 | Announcement | Automotive Security Leaders Must Take Immediate Action to Mitigate the Surging Cyber Threats--Upstream Report Reveals Critical Gaps |
| 06 Jan 2025 | Announcement | Upstream Bio to Present at the 43rd Annual J.P. Morgan Healthcare Conference |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |